Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RIAZ BABER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1740365808
CMS profile
169404
Location
NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$17.48

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $17.48 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
LivaNova USA, Inc. $17.48 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RIAZ BABER

NPI 1740365808 · CMS profile ID 169404

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

NAPERVILLE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). RIAZ BABER, NPI 1740365808, CMS profile ID 169404. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
RIAZ BABER, NPI 1740365808, CMS profile ID 169404, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1740365808?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $17.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LivaNova USA, Inc. $17.4810/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 711985543 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $17.48 1
PY2021 $25.10 1
PY2022 $90.37 4
PY2023 $52.86 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $341,122.24 185
PY2024 Principal investigator $389,598.32 164
PY2023 Recipient $20,894.00 17
PY2023 Principal investigator $262,289.24 63
PY2022 Recipient $8,539.60 3
PY2022 Principal investigator $221,491.86 60
PY2021 Recipient $40,104.00 15
PY2021 Principal investigator $235,417.23 45
PY2020 Principal investigator $547,839.81 74
PY2019 Recipient $1,141.05 5
PY2019 Principal investigator $378,637.76 82

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

80 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $408.19 12/31/2023 Non-covered Recipient Entity
AMR-BABER-RESEARCH INC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 998413081
Principal investigator 1 ABBVIE INC. $200.00 12/31/2023 Non-covered Recipient Entity
BABER RESEARCH GROUP
Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD No dispute reported 06/30/2026 998413187
Principal investigator 1 ACADIA Pharmaceuticals Inc $5,245.25 12/12/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1028880873
Recipient PFIZER INC. $610.00 12/07/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046348029
Recipient PFIZER INC. $722.50 12/07/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046378269
Recipient PFIZER INC. $1,219.73 12/07/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046398471
Recipient PFIZER INC. $610.00 12/07/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046398631
Principal investigator 1 PFIZER INC. $1,200.00 11/22/2023 Non-covered Recipient Entity
1
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046382769
Principal investigator 1 PFIZER INC. $4,529.26 11/22/2023 Non-covered Recipient Entity
1
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046386353
Principal investigator 1 ACADIA Pharmaceuticals Inc $15,184.54 11/20/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1028880567
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,841.68 11/14/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1028880425
Principal investigator 1 ACADIA Pharmaceuticals Inc $13,490.19 11/14/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1028880531
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,400.00 11/06/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1028880115
Principal investigator 1 Janssen Research & Development, LLC $421.00 10/23/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 986140087
Principal investigator 1 Janssen Research & Development, LLC $3,048.00 10/23/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 986140089
Recipient PFIZER INC. $3,287.48 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046423423
Recipient PFIZER INC. $893.47 10/19/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046425643
Principal investigator 1 LivaNova USA, Inc. $695.00 10/17/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043070409
Principal investigator 1 LivaNova USA, Inc. $70.00 10/17/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043070870
Principal investigator 1 ACADIA Pharmaceuticals Inc $8,100.11 10/11/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1028879925
Principal investigator 1 LivaNova USA, Inc. $265.00 10/10/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043069751
Principal investigator 1 LivaNova USA, Inc. $1,155.00 10/10/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043071439
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,281.67 10/09/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1028879773
Principal investigator 1 LivaNova USA, Inc. $328.24 10/03/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043048005
Recipient PFIZER INC. $1,219.73 09/26/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046386438
Principal investigator 1 LivaNova USA, Inc. $4,122.90 09/06/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047989
Principal investigator 1 LivaNova USA, Inc. $3,873.15 09/01/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047939
Principal investigator 1 LivaNova USA, Inc. $520.96 09/01/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047955
Principal investigator 1 LivaNova USA, Inc. $266.29 09/01/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047971
Principal investigator 1 Janssen Research & Development, LLC $7,727.00 08/31/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 986140085
Principal investigator 1 LivaNova USA, Inc. $235.24 08/23/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047920
Principal investigator 1 LivaNova USA, Inc. $532.58 08/18/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047885
Principal investigator 1 LivaNova USA, Inc. $5,787.45 08/18/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047901
Principal investigator 1 LivaNova USA, Inc. $687.15 08/10/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047869
Principal investigator 1 LivaNova USA, Inc. $525.00 08/08/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043069187
Principal investigator 1 ACADIA Pharmaceuticals Inc $963.58 08/07/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-070 No dispute reported 06/30/2026 1028878695
Recipient PFIZER INC. $7,468.43 08/03/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046443143
Principal investigator 1 LivaNova USA, Inc. $4,256.55 08/01/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047833
Principal investigator 1 LivaNova USA, Inc. $266.29 08/01/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047849
Principal investigator 1 Janssen Research & Development, LLC $5,874.00 07/27/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 986140083
Principal investigator 1 ACADIA Pharmaceuticals Inc $11,517.53 07/24/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1028878513
Principal investigator 1 LivaNova USA, Inc. $4,857.30 07/18/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047799
Principal investigator 1 LivaNova USA, Inc. $1,410.76 07/18/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047815
Principal investigator 1 LivaNova USA, Inc. $267.30 07/13/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047783
Principal investigator 1 PFIZER INC. $893.47 07/13/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046447457
Principal investigator 1 LivaNova USA, Inc. $1,898.10 07/04/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047765
Principal investigator 1 LivaNova USA, Inc. $392.85 06/28/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047747
Principal investigator 1 ACADIA Pharmaceuticals Inc $10,072.77 06/19/2023 Non-covered Recipient Entity
AMR BABER RESEARCH GROUP INC
ACP-103-069 No dispute reported 06/30/2026 1028878003
Principal investigator 1 LivaNova USA, Inc. $4,156.65 06/13/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047731
Principal investigator 1 PFIZER INC. $3,287.48 06/08/2023 Non-covered Recipient Entity
BABER RESEARCH GROUP
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046420075
Principal investigator 1 LivaNova USA, Inc. $266.29 06/01/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047710
Principal investigator 1 LivaNova USA, Inc. $3,820.50 05/30/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047697
Principal investigator 1 ABBVIE INC. $6,000.00 05/25/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder No dispute reported 06/30/2026 998384601
Principal investigator 1 ABBVIE INC. $2,500.00 05/25/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder No dispute reported 06/30/2026 998384603
Principal investigator 1 LivaNova USA, Inc. $6,446.25 05/16/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047679
Principal investigator 1 LivaNova USA, Inc. $4,509.00 05/03/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047663
Principal investigator 1 LivaNova USA, Inc. $1,119.15 04/26/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047631
Principal investigator 1 LivaNova USA, Inc. $266.29 04/26/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047647
Principal investigator 1 LivaNova USA, Inc. $798.87 04/20/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047613
Principal investigator 1 Janssen Research & Development, LLC $5,746.00 04/17/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Short term Exploratory Study to Evaluate Safety Tolerability and Pharmacokinetics of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents with Major Depressive Disorder Who Have an Inadequate Response to an SSRI and Psychotherapy No dispute reported 06/30/2026 986140081
Principal investigator 1 LivaNova USA, Inc. $27,421.20 04/13/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047595
Recipient PFIZER INC. $3,484.36 04/06/2023 Covered Recipient Physician PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046464602
Recipient ACADIA Pharmaceuticals Inc $32.34 03/17/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868099
Recipient ACADIA Pharmaceuticals Inc $55.50 03/17/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868111
Recipient ACADIA Pharmaceuticals Inc $14.54 03/17/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868129
Recipient ACADIA Pharmaceuticals Inc $60.94 03/17/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868143
Recipient ACADIA Pharmaceuticals Inc $14.09 03/17/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868157
Recipient ACADIA Pharmaceuticals Inc $29.10 03/17/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868173
Recipient ACADIA Pharmaceuticals Inc $1,046.80 03/16/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868072
Recipient ACADIA Pharmaceuticals Inc $124.99 03/16/2023 Covered Recipient Physician ACP-103-069_070 No dispute reported 06/30/2026 1028868087
Principal investigator 1 LivaNova USA, Inc. $70.00 02/21/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043067781
Principal investigator 1 LivaNova USA, Inc. $695.00 02/21/2023 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
The RECOVER sUb-study, which leverages quaNtitative and Credible research tOols from Verily, will providE assessment measuRes for depressive episodes (UNCOVER) No dispute reported 06/30/2026 1043068743
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $4,180.95 02/09/2023 Non-covered Recipient Entity
BABER RESEARCH GROUP
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046573455
Principal investigator 1 LivaNova USA, Inc. $22,792.05 02/09/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043047575
Principal investigator 1 ABBVIE INC. $10,000.00 01/25/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
An 8-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Cariprazine in the Treatment of Pediatric Subjects (5 to 17 Years of Age) With Autism Spectrum Disorder No dispute reported 06/30/2026 998367231
Principal investigator 1 LivaNova USA, Inc. $266.29 01/25/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043047565
Principal investigator 1 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. $5,400.68 01/12/2023 Non-covered Recipient Entity
BABER RESEARCH GROUP
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1046573437
Principal investigator 1 ABBVIE INC. $11,500.00 01/11/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Study of the Change in Disease State and Safety of Oral Cariprazine Capsules in the Treatment of Depression in Pediatric Participants (10 to 17 Years of Age) With Bipolar I Disorder No dispute reported 06/30/2026 998364877
Principal investigator 1 LivaNova USA, Inc. $10,000.00 01/06/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) No dispute reported 06/30/2026 1043046889
Principal investigator 1 LivaNova USA, Inc. $235.24 01/06/2023 Non-covered Recipient Entity
AMR BABER RESEARCH INC
TheRECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER) No dispute reported 06/30/2026 1043046905